Literature DB >> 20623888

[Hyperemesis gravidarum: a rare but potentially severe complication of the first trimester of pregnancy].

Lucie Macle1, Marie-Noëlle Varlet, Pascal Cathébras.   

Abstract

Although nausea and vomiting are common symptoms in early pregnancy, hyperemesis gravidarum (HG) is a rare complication of the first trimester of pregnancy. This condition is defined as intractable vomiting occurring before 20 weeks of gestation, with fluid and electrolyte disturbance, significant weight loss, and ketonuria, leading to hospitalization in the absence of other cause than pregnancy. Some biological disturbances found in HG, such as hyperthyroidism and hepatic cytolysis, which are correlated with the importance of vomiting, are without severe clinical consequences, but may represent diagnostic pitfalls. The aetiology is unknown, but human chorionic gonadotropin hormones likely play the first role. Psychological disturbance is currently seen as the result of the burden and stress of HG rather than a causal factor. Maternal outcome may be severe in the absence of treatment, but pregnancy outcome seems good, as far as the condition has been adequately controlled. The management of HG includes IV rehydration, thiamine supplementation, antiemetic drugs (doxylamine, metoclopramide and chlorpromazine being the first-line choices), and in severe cases, nasogastric or parenteral nutrition. A psychological support is often necessary.

Entities:  

Mesh:

Year:  2010        PMID: 20623888

Source DB:  PubMed          Journal:  Rev Prat        ISSN: 0035-2640


  1 in total

1.  Comparison of the pharmacokinetics of a new 30 mg modified-release tablet formulation of metoclopramide for once-a-day administration versus 10 mg immediate-release tablets: a single and multiple-dose, randomized, open-label, parallel study in healthy male subjects.

Authors:  Roberto Bernardo-Escudero; Rosalba Alonso-Campero; María Teresa de Jesús Francisco-Doce; Myriam Cortés-Fuentes; Miriam Villa-Vargas; Juan Angeles-Uribe
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2012-02-11       Impact factor: 2.441

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.